Announcements Trials

Browse Landscape

Phase

Phase 1/2 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 145 Lymphoma 104 Lymphoma, Large B-Cell, Diffuse 76 Sarcoma 62 Hodgkin Disease 46 Precursor Cell Lymphoblastic Leukemia-Lymphoma 38 Burkitt Lymphoma 35 Triple Negative Breast Neoplasms 31 Lymphoma, Non-Hodgkin 29 Lymphoma, Mantle-Cell 27 Leukemia 25 Neoplasms 22 Lymphoma, Follicular 22 Neoplasm Metastasis 21 Multiple Myeloma 21 Neuroblastoma 20 Carcinoma, Hepatocellular 18 Ovarian Neoplasms 16 Lymphoma, B-Cell 16 Liver Neoplasms 14 Urinary Bladder Neoplasms 12 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 12 Osteosarcoma 12 Lymphoma, T-Cell, Peripheral 11 Lymphoma, Large-Cell, Anaplastic 11 Inflammatory Breast Neoplasms 11 Breast Neoplasms, Male 11 Prostatic Neoplasms 10 Dendritic Cell Sarcoma, Interdigitating 10 Lymphoma, Large-Cell, Immunoblastic 9

Interventions

pazopanib 1 eribulin 1 Trabectedin 1 Doxorubicin 1 Dasatinib 1 Dacarbazine 1 Axitinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Solitary Fibrous Tumors × Doxorubicin × Clear all

NCT03023124 2024-12-09

STRADA

Italian Sarcoma Group

Phase 2 Completed

Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡